Uveal melanoma, a rare and aggressive form of eye cancer, has just witnessed a groundbreaking development in its treatment landscape. The Food and Drug Administration (FDA) recently granted approval to the HEPZATO KIT, an innovative liver-directed therapy that offers new hope to adult patients with uveal melanoma and unresectable hepatic metastases.









